Yongyan Chen

Immunology and Microbiology · Life Sciences

34h-index4.8kcitations82works7.72yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune Cell Function and Interaction(42), Cancer Immunotherapy and Biomarkers(15), Immune cells in cancer(15), T-cell and B-cell Immunology(14), Immune Response and Inflammation(13)

Publications82 total

Innate lymphoid cells originate from fetal liver–derived tissue-resident progenitors
Science Immunology·2025· 7 cited
Unravelling the role of gut microbiota in acute pancreatitis: integrating Mendelian randomization with a nested case–control study
Frontiers in Microbiology·2024· 3 citedOpen Access
Hepatocyte-derived FGL1 accelerates liver metastasis and tumor growth by inhibiting CD8+ T and NK cells
JCI Insight·2024· 13 citedOpen Access
Spatial transcriptomics reveals a low extent of transcriptionally active hepatitis B virus integration in patients with HBsAg loss
Gut·2023· 35 citedOpen Access
Data from Antiapoptotic Activity of Autocrine Interleukin-22 and Therapeutic Effects of Interleukin-22-Small Interfering RNA on Human Lung Cancer Xenografts
2023Open Access
Data from Antiapoptotic Activity of Autocrine Interleukin-22 and Therapeutic Effects of Interleukin-22-Small Interfering RNA on Human Lung Cancer Xenografts
2023Open Access
Data from TLR2 Limits Development of Hepatocellular Carcinoma by Reducing IL18-Mediated Immunosuppression
2023Open Access
Supplementary Figure 5 from TLR2 Limits Development of Hepatocellular Carcinoma by Reducing IL18-Mediated Immunosuppression
2023Open Access
Supplementary Figure 7 from TLR2 Limits Development of Hepatocellular Carcinoma by Reducing IL18-Mediated Immunosuppression
2023Open Access
Supplementayr Figure 6 from TLR2 Limits Development of Hepatocellular Carcinoma by Reducing IL18-Mediated Immunosuppression
2023Open Access
Supplementary Methods, Figure Legends from TLR2 Limits Development of Hepatocellular Carcinoma by Reducing IL18-Mediated Immunosuppression
2023Open Access
Supplementary Figure 4 from TLR2 Limits Development of Hepatocellular Carcinoma by Reducing IL18-Mediated Immunosuppression
2023Open Access
Data from TLR2 Limits Development of Hepatocellular Carcinoma by Reducing IL18-Mediated Immunosuppression
2023Open Access
Supplementary Figure 2 from TLR2 Limits Development of Hepatocellular Carcinoma by Reducing IL18-Mediated Immunosuppression
2023Open Access
Supplementary Methods, Figure Legends from TLR2 Limits Development of Hepatocellular Carcinoma by Reducing IL18-Mediated Immunosuppression
2023Open Access
Supplementary Figure 7 from TLR2 Limits Development of Hepatocellular Carcinoma by Reducing IL18-Mediated Immunosuppression
2023Open Access
Supplementayr Figure 6 from TLR2 Limits Development of Hepatocellular Carcinoma by Reducing IL18-Mediated Immunosuppression
2023Open Access
Supplementary Figure 3 from TLR2 Limits Development of Hepatocellular Carcinoma by Reducing IL18-Mediated Immunosuppression
2023Open Access
Supplementary Figure 3 from TLR2 Limits Development of Hepatocellular Carcinoma by Reducing IL18-Mediated Immunosuppression
2023Open Access
Supplementary Figure 5 from TLR2 Limits Development of Hepatocellular Carcinoma by Reducing IL18-Mediated Immunosuppression
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Zhigang Tian(42), Haiming Wei(32), Rui Sun(32), Xiaodong Zheng(7), Min Cheng(7), Xiaolei Hao(6), Zhe‐Xiong Lian(6), Hui Peng(4), Fenglei Li(4), Li Bai(4), Jian Zhang(3), Jian Wang(3), Jiacheng Bi(2), Xiang Gao(2), Rongbin Zhou(2), Jian Zhang(2), Cheng Sun(2), Xunyao Wu(2), Tingting Li(2), Yanshi Wang(2)